David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]
Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.
Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]
Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]
Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.
The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. Read the full story.
GigaGen announced that it is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19, the pandemic coronavirus that has been sweeping the world and for which humans have no innate immunity. Based in South San Francisco, GigaGen spent the first seven years of its existence developing its single cell technology drug discovery and […]
Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. But a small South San Francisco startup thinks its approach could be even better. Read the full […]
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. Read the full press release.
The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for […]
“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable […]
With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health […]
A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients. IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them […]
Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday. […]
Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]
Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Nature Biotechnology: Convalescent serum lines up as first-choice treatment for coronavirus
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
TIME: Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]
WGNO-TV (ABC): Coronavirus Survivors Needed: New Orleans Doctor is collecting blood samples from survivors to make treatment
Watch the tv news report.
GEN: Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development
Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.
The Lens: Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment
Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]
Chemical & Engineering News: Searching for a coronavirus cure in the blood: Scientists look to convalescent plasma, hyperimmune therapy, and monoclonal antibodies to treat COVID-19
Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]
Pharmaceutical Technology: GigaGen works on recombinant polyclonal antibody against Covid-19
Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.
San Francisco Business Times: Peninsula biotech readies attack on COVID-19 — all it needs now is more cash and recovered patients’ blood
The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.
BioSpace: GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals. Read the full story.
Big4Bio: GigaGen Focuses Its Technology to Address COVID-19 Pandemic
GigaGen announced that it is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19, the pandemic coronavirus that has been sweeping the world and for which humans have no innate immunity. Based in South San Francisco, GigaGen spent the first seven years of its existence developing its single cell technology drug discovery and […]
FierceBiotech: GigaGen jumps into COVID-19 arena with polyclonal antibodies
Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. But a small South San Francisco startup thinks its approach could be even better. Read the full […]
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. Read the full press release.
Pharma’s Almanac: CEO Dave Johnson shares his thoughts in Roundtable: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?
The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for […]
GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts
“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable […]
Scrip: CEO Dave Johnson Discusses Commercializing Advanced Therapies in Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business and Investment
With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health […]
BioSpace: GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage
A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients. IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them […]
Biocom: CSO Adam Adler named a Biocom Catalyst Award Winner
Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday. […]
PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People
Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell […]
GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]